Get the Stockscreener App
86.74
0.54%
0.47
After Hours:
86.74
Apogee Therapeutics Inc stock is traded at $86.74, with a volume of 355.85K.
It is up +0.54% in the last 24 hours and up +20.64% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$86.27
Open:
$86.16
24h Volume:
355.85K
Relative Volume:
0.34
Market Cap:
$6.47B
Revenue:
-
Net Income/Loss:
$-255.84M
P/E Ratio:
-20.58
EPS:
-4.2149
Net Cash Flow:
$-232.60M
1W Performance:
+3.25%
1M Performance:
+20.64%
6M Performance:
+60.72%
1Y Performance:
+172.77%
1-Day Range:
$85.15
$88.99
1-Week Range:
$81.27
$88.99
52-Week Range:
$31.21
$88.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
86.74 | 6.44B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
440.05 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.46 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
809.27 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.00 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.64 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing - Moomoo
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise - Sahm
Aug PreEarnings: Will Apogee Therapeutics Inc benefit from seasonalityPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Should value investors consider Apogee Therapeutics IncQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Apogee Therapeutics CEO Henderson sells $1.65 million in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CEO Henderson sells $1.65 million in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under Rule 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 85.95 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 85.95 USD - Investing.com
T. Rowe Price (APGE) discloses 10.29M shares, 16.8% stake in Apogee - Stock Titan
Trade Recap: Whats the beta of Apogee Therapeutics Inc stockWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - Investing.com
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan - Stock Titan
Responsive Playbooks and the APGE Inflection - Stock Traders Daily
APGE Technical Analysis & Stock Price Forecast - Intellectia AI
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Deutsche Bank Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $118 - Moomoo
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE - marketbeat.com
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - Moomoo
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Rankings: Will Apogee Therapeutics Inc benefit from seasonalityEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - Investing.com South Africa
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat
Mizuho raises Apogee Therapeutics stock price target on AD data By Investing.com - Investing.com South Africa
Mizuho raises Apogee Therapeutics stock price target on AD data - Investing.com
Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - Moomoo
Apogee Therapeutics announces $300 million public offering - MSN
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):